AL
ALX Oncology Holdings Inc.
ALXO · NASDAQ
$1.94 +1.57% (+$0.03)
1M -1.52%
Market Cap $255.7M
P/E Ratio -
Div. Yield -
ROE 90.30%
Bulios Fair Price
$1.54
20.6% downside
Current Price
$1.94
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ALXO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
91 /100
Cheap P/B 1.88x
P/E N/A
P/FFO N/A
Growth
0 /100
Declining Book val. growth 53.80%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 56.53%
Asset turnover 0.00x
ROE 90.30%
Debt
69 /100
Low Debt/Equity 0.07x
Int. coverage -56.49x
Current ratio 9.71x
Stability
47 /100
Moderate Beta 0.40x
Profitable years 0
EPS volatility 30.18%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ALXO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jason Lettmann
Employees
48
Headquarters
South San Francisco
Upcoming events
06 NOV
Earnings
Upcoming earnings report